A comparative study of oral and percutaneous bisoprolol

A comparative study of oral and percutaneous bisoprolol - A comparative study of oral and percutaneous bisoprolol

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031538

Enrollment

Registered

2018-03-01

Start date

2018-02-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure, Hypertension

Interventions

Oral bisoprolol (1.25 to 5 mg, once / day, 6 months) percutaneous bisoprolol (2 to 8 mg, once / day, 6 months)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic heart failure or hypertensive patient

Exclusion criteria

Exclusion criteria: sinus bradycardia at rest (<50/min) second -or third-degree AV block Doctor's decision not to register to this regimen

Design outcomes

Primary

Measure	Time frame
Herat rate (Holter ECG)	—

Secondary

Measure	Time frame
BNP Blood pressure UCG	—

Countries

Japan

Contacts

Public ContactMitsue Akiyama

Sekino Laboratory Department of Research

skn-np@sekino-hospital.com03-3986-5501

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026